GYNECOLOGIC CANCERS

"Although I am disappointed that the PFS improvement was not statistically significant, I look forward to continuing to follow these results," Robert Coleman, MD.

Early phase 2 data show IMNN-001 added to chemo plus bevacizumab reduces residual ovarian cancer, boosts ctDNA clearance, and remains well tolerated.

A trend toward improvement in overall survival (OS) with pembrolizumab was observed; however, the OS data are not mature.

National BRFSS study reveals SOGI adults lag in cervical and breast cancer screening; gaps are linked to insurance, access, and stigma.

Puxitatug samrotecan is now being evaluated in the global phase 3 BLUESTAR-Endometrial-01 trial.

FDA clears automated PD-L1 22C3 testing on Dako Omnis for 4 more tumors, streamlining labs and guiding Keytruda therapy decisions.

ROSELLA update shows consistent OS benefit with relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, irrespective of prior taxane use.

"Sac-TMT may be able to address a critical unmet need for certain patients with advanced endometrial cancer," said Domenica Lorusso, MD, PhD.

Intraperitoneal rintatolimod may boost outcomes with immunotherapies such as pembrolizumab in ovarian cancer.

Robert Coleman, MD, discusses how relacorilant plus nab‑paclitaxel boosts survival in platinum‑resistant ovarian cancer.

Dr Alexander Olawaiye discusses the impact of the FDA approval of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Premal Thaker, MD, MS, discusses IMNN-001 boosts overall survival in advanced ovarian cancer, with bigger gains alongside PARP inhibitors, as phase 3 OVATION 3 ramps up.

Rezatapopt showed clinical activity across subgroups in patients with TP53 Y220C-mutated ovarian cancer in the phase 2 PYNNACLE trial.

Enrollment restarts in a phase 2 ovarian and clear cell gynecologic cancer study after FDA lifts hold on PD-1/CTLA-4 DART therapy.